Compare AIRE & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | KALA |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.3M |
| IPO Year | 2023 | 2017 |
| Metric | AIRE | KALA |
|---|---|---|
| Price | $1.36 | $0.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.30 | ★ $31.50 |
| AVG Volume (30 Days) | 88.1K | ★ 364.1K |
| Earning Date | 04-28-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.34 | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.16 | $0.07 |
| 52 Week High | $3.98 | $19.77 |
| Indicator | AIRE | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 36.00 |
| Support Level | $1.29 | $0.51 |
| Resistance Level | $1.85 | $0.72 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 26.53 | 18.67 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.